^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    autogene cevumeran (RG6180)

    i
    Company:
    BioNTech, Roche
    Drug class:
    Immunostimulant
    Related drugs:
    Apply
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962)
    Phase 1
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    04/26/2024
    Initiation :
    12/21/2017
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR negative
    |
    Tecentriq (atezolizumab) • autogene cevumeran (RG6180)